| scholarly article | Q13442814 |
| P818 | arXiv ID | 1705.05921 |
| P6179 | Dimensions Publication ID | 1085379452 |
| P356 | DOI | 10.1038/S41598-017-02178-1 |
| P932 | PMC publication ID | 5434051 |
| P698 | PubMed publication ID | 28512298 |
| P2093 | author name string | Kirill S Korolev | |
| Ana B Pavel | |||
| P2860 | cites work | Fitness and its role in evolutionary genetics | Q22122004 |
| Interference among deleterious mutations favours sex and recombination in finite populations | Q22122238 | ||
| Cancer genome landscapes | Q22242276 | ||
| Hallmarks of Cancer: The Next Generation | Q22252312 | ||
| Near-neutrality in evolution of genes and gene regulation | Q24541501 | ||
| The role of chromosomal instability in tumor initiation | Q24541508 | ||
| ErbB receptors: from oncogenes to targeted cancer therapies | Q24683709 | ||
| Response of foot-and-mouth disease virus to increased mutagenesis: influence of viral load and fitness in loss of infectivity | Q27470003 | ||
| Exploration, normalization, and summaries of high density oligonucleotide array probe level data | Q27861098 | ||
| Signal transduction by the platelet-derived growth factor receptor | Q28251437 | ||
| Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib | Q28263625 | ||
| R Regulation of tumor angiogenesis and metastasis by FGF and PDGF signaling pathways | Q28275289 | ||
| DNA topoisomerases and their poisoning by anticancer and antibacterial drugs | Q28284744 | ||
| Molecular mechanisms of fibroblast growth factor signaling in physiology and pathology | Q28291993 | ||
| Somatic mutation, genomic variation, and neurological disease | Q28395313 | ||
| Assessment of pharmacogenomic agreement | Q28597117 | ||
| Antibody neutralization and escape by HIV-1 | Q29547345 | ||
| The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity | Q29547693 | ||
| Circular binary segmentation for the analysis of array-based DNA copy number data | Q29615406 | ||
| MAP kinase signalling pathways in cancer | Q29615542 | ||
| Cell cycle checkpoint signaling through the ATM and ATR kinases | Q29617837 | ||
| Genetic basis for clinical response to CTLA-4 blockade in melanoma | Q29620594 | ||
| Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis | Q30311954 | ||
| GSVA: gene set variation analysis for microarray and RNA-seq data. | Q30586230 | ||
| Integrating mutation and gene expression cross-sectional data to infer cancer progression | Q31039903 | ||
| Integrative modeling of multi-omics data to identify cancer drivers and infer patient-specific gene activity | Q31044138 | ||
| Integrating heterogeneous drug sensitivity data from cancer pharmacogenomic studies. | Q31109155 | ||
| Identifying cancer type specific oncogenes and tumor suppressors using limited size data | Q31135256 | ||
| Human cancers express mutator phenotypes: origin, consequences and targeting | Q33554201 | ||
| Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines | Q33742964 | ||
| The temporal order of genetic and pathway alterations in tumorigenesis | Q34070603 | ||
| Accumulation of driver and passenger mutations during tumor progression | Q34276850 | ||
| Review of epidermal growth factor receptor biology | Q34320636 | ||
| Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome | Q34381630 | ||
| Tug-of-war between driver and passenger mutations in cancer and other adaptive processes | Q34409055 | ||
| Tobacco, colorectal cancer, and adenomas: a review of the evidence | Q34409468 | ||
| Inconsistency in large pharmacogenomic studies | Q34541198 | ||
| Negative clonal selection in tumor evolution | Q34587078 | ||
| G-protein-coupled receptors and cancer. | Q34606002 | ||
| Evolutionary triage governs fitness in driver and passenger mutations and suggests targeting never mutations. | Q34662452 | ||
| Paradoxical relationship between chromosomal instability and survival outcome in cancer | Q34988001 | ||
| BRCA1 regulation of epidermal growth factor receptor (EGFR) expression in human breast cancer cells involves microRNA-146a and is critical for its tumor suppressor function | Q36539643 | ||
| Impact of deleterious passenger mutations on cancer progression | Q36637272 | ||
| The IGF-I signaling pathway | Q36754655 | ||
| Signal integration by JNK and p38 MAPK pathways in cancer development | Q37560607 | ||
| High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma | Q38926293 | ||
| Back to the future: revisiting HIV-1 lethal mutagenesis | Q39511261 | ||
| The mutational meltdown in asexual populations | Q41067565 | ||
| Fitness of RNA virus decreased by Muller's ratchet | Q41211936 | ||
| The effect of deleterious alleles on adaptation in asexual populations. | Q42534673 | ||
| Turning ecology and evolution against cancer | Q46904792 | ||
| Mutation-selection networks of cancer initiation: tumor suppressor genes and chromosomal instability. | Q52012209 | ||
| The accumulation of deleterious genes in a population--Muller's Ratchet | Q67444775 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P4510 | describes a project that uses | GSVA | Q113334751 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cell line | Q21014462 |
| cancer cell line | Q23058136 | ||
| P304 | page(s) | 1938 | |
| P577 | publication date | 2017-05-16 | |
| P1433 | published in | Scientific Reports | Q2261792 |
| P1476 | title | Genetic load makes cancer cells more sensitive to common drugs: evidence from Cancer Cell Line Encyclopedia | |
| P478 | volume | 7 |
Search more.